CN113729211A - Composition and preparation method and application thereof - Google Patents
Composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN113729211A CN113729211A CN202110892765.0A CN202110892765A CN113729211A CN 113729211 A CN113729211 A CN 113729211A CN 202110892765 A CN202110892765 A CN 202110892765A CN 113729211 A CN113729211 A CN 113729211A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- composition
- children
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 71
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 48
- 239000006041 probiotic Substances 0.000 claims abstract description 33
- 235000018291 probiotics Nutrition 0.000 claims abstract description 33
- 230000000529 probiotic effect Effects 0.000 claims abstract description 29
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 27
- 235000013336 milk Nutrition 0.000 claims abstract description 26
- 210000004080 milk Anatomy 0.000 claims abstract description 26
- 239000008267 milk Substances 0.000 claims abstract description 26
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960000304 folic acid Drugs 0.000 claims abstract description 24
- 235000019152 folic acid Nutrition 0.000 claims abstract description 24
- 239000011724 folic acid Substances 0.000 claims abstract description 24
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 24
- 239000011707 mineral Substances 0.000 claims abstract description 24
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 21
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 21
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 21
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 21
- 230000012010 growth Effects 0.000 claims abstract description 20
- 238000011161 development Methods 0.000 claims abstract description 19
- 229960000342 retinol acetate Drugs 0.000 claims abstract description 10
- 235000019173 retinyl acetate Nutrition 0.000 claims abstract description 10
- 239000011770 retinyl acetate Substances 0.000 claims abstract description 10
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims abstract description 10
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 25
- 239000002671 adjuvant Substances 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 5
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 235000013406 prebiotics Nutrition 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 235000021552 granulated sugar Nutrition 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 235000015097 nutrients Nutrition 0.000 abstract description 5
- 235000021590 normal diet Nutrition 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 235000010755 mineral Nutrition 0.000 description 19
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 18
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 229960003471 retinol Drugs 0.000 description 11
- 235000020944 retinol Nutrition 0.000 description 11
- 239000011607 retinol Substances 0.000 description 11
- -1 retinol compound Chemical class 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229960005069 calcium Drugs 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 6
- 229930003316 Vitamin D Natural products 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- 235000019166 vitamin D Nutrition 0.000 description 6
- 239000011710 vitamin D Substances 0.000 description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 description 6
- 229940045997 vitamin a Drugs 0.000 description 6
- 229940046008 vitamin d Drugs 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 229940057917 medium chain triglycerides Drugs 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000021049 nutrient content Nutrition 0.000 description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010054877 Mucosal discolouration Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 208000035362 autoimmune disorder of the nervous system Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000020988 fatty fish Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 208000012307 pale mucous membrane Diseases 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910001868 water Inorganic materials 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
Abstract
The application discloses a composition, a preparation method and application thereof, wherein the composition comprises the following components: 50-65 parts by weight of medium chain triglyceride; 80-120 parts of milk mineral salt; 80-120 parts of DHA powder; 0.0006 to 0.001 weight part of cholecalciferol; 150 portions of probiotic powder and 180 portions of probiotic powder; 0.018-0.03 weight portion of folic acid; 0.015-0.025 parts by weight of retinol acetate. The invention aims at the problem of the growth and development of children at present, supplements nutrient components which are difficult to meet with normal diet in proper amount, is different from the traditional health food for children, has poor children acceptability, is prepared into powder, has good taste after dissolving, can improve the compliance of children, is beneficial to improving the matching degree of children and better improves the nutritional development.
Description
Technical Field
The application provides a composition, a preparation method and application thereof, and belongs to the technical field of health-care food.
Background
The childhood period is an important period for the growth and development of people in life, and the reasonable diet and sufficient nutrition obtained in the childhood period have very important significance for the physical and mental health of children. The united nations foundation issued 2019 world child status on 10, 15, 2019: children, food and nutrition, reports indicate that 1.49 million children are slow growing or too short for the same age around the world; 5000 ten thousand children are thin or too thin; 3.4 million children (i.e., one in every two children) are deficient in essential vitamins and minerals, such as vitamin A. Inadequate nutrition can lead to growth retardation and poor cognitive abilities in children and adolescents. Deficiency of micronutrients can lead to growth and development disorders, low immunity and tissue development disorders, poor health, and the like.
In summary, there is an urgent need for a safe, effective and convenient food for promoting the growth and development of children.
At present, the commonly used methods for promoting the growth and development of children include a food supplement method, a nutrient supplement mixed food method and the like. But the food nourishing method has little effect, has higher requirements on the nutrition knowledge storage of parents, the diet concept and the matching degree of children, and can generate potential safety hazards on the health of children due to improper traditional Chinese medicine food nourishing; aiming at the problems that the nutrient supplements for children are various in types, the combined effect is not clear, and the nutrient proportion imbalance is difficult to guarantee for the healthy growth of the children.
Disclosure of Invention
According to one aspect of the application, a composition for promoting the growth and development of children, which is safe, effective and convenient to take, is provided; the product is prepared into powder, has good taste, can improve the compliance of children taking, is beneficial to improving the matching degree of children and better improves the nutritional development.
According to a first aspect of the present application, there is provided a composition comprising the following components:
50-65 parts by weight of medium chain triglyceride;
80-120 parts of milk mineral salt;
80-120 parts of DHA powder;
0.0006 to 0.001 weight part of cholecalciferol;
150 portions of probiotic powder and 180 portions of probiotic powder;
0.018-0.03 weight portion of folic acid;
0.015-0.025 parts by weight of retinol acetate;
the DHA powder contains DHA with the mass content of more than or equal to 10%.
Preferably, the composition comprises the following components:
52.5-63.5 parts by weight of medium chain triglyceride;
80-120 parts of milk mineral salt;
80-120 parts of DHA powder;
0.0006 to 0.001 weight part of cholecalciferol;
150 portions of probiotic powder and 180 portions of probiotic powder;
0.018-0.03 weight portion of folic acid;
0.015-0.025 parts by weight of retinol acetate.
Optionally, the probiotic powder comprises bifidobacterium animalis Bb-12 and prebiotics.
Optionally, the prebiotic comprises stachyose and galactooligosaccharide.
Optionally, the mass ratio of the galactooligosaccharide, the stachyose and the bifidobacterium animalis Bb-12 is 15:10: 1.
Optionally, the composition further comprises an auxiliary material; the adjuvant is at least one selected from oligomeric maltose powder, white granulated sugar powder, maltodextrin, and ascorbic acid.
Optionally, in the composition, the mass ratio of the auxiliary material to the medium-chain triglyceride is 525-: 50-65.
Optionally, the composition consists of:
50-65 parts by weight of medium chain triglyceride;
80-120 parts of milk mineral salt;
80-120 parts of DHA powder;
0.0006 to 0.001 weight part of cholecalciferol;
150 portions of probiotic powder and 180 portions of probiotic powder;
0.018-0.03 weight portion of folic acid;
0.015-0.025 parts by weight of retinol acetate;
the auxiliary material 525 and 635;
preferably, the composition is a powder.
The milk mineral salt is derived from cow milk, and is a milk calcium substance with high calcium content obtained by performing membrane separation on calcium and mineral salt naturally existing in cow milk. The main component of the calcium phosphate calcium milk powder is calcium phosphate, and in addition, the calcium phosphate calcium milk powder also comprises protein, lactose, zinc, phosphorus, sodium, potassium, magnesium and other rich nutrient components, the calcium content is about 23-28%, and the ratio of calcium to phosphorus is 2:1, so that the calcium phosphate calcium milk powder is more beneficial to absorption by a human body. The calcium lactate salt has the functions of enhancing bone mineral density and calcium strengthening.
MCT (medium chain triglycerides) are derived in nature mainly from coconut oil, palm kernel oil, breast milk, milk and their preparations. MCT can be quickly digested and absorbed in human body, can be oxidized and supplied with energy, can reduce the requirement on blood sugar, and is not stored in tissues such as fat, liver, muscle and the like of the human body like LCT, so the MCT has obvious effects of inhibiting weight gain and preventing obesity. MCT has certain effect on improving metabolism of sugar, lipid and cholesterol, and also has effects of enhancing immunity, enhancing gluconeogenesis, improving memory and cognitive ability, improving body composition and cardiovascular health.
Sunlight irradiation is a main source of vitamin D in human bodies, and the generation of vitamin D3 can be influenced by the time, age, latitude, glass and sun cream of sunlight irradiation. In older children, the dietary intake of vitamin D is very small, and only a few fatty fish, egg yolk, nuts and some fungi contain a small amount of vitamin D, which cannot meet the growth requirements of children. Vitamin D is an important element for regulating calcium and phosphorus in human bodies and plays an important role in the skeletal development process. Suitable vitamin D is vital to the health of the organism, and vitamin D deficiency is closely related to occurrence and development of a plurality of diseases, including bone diseases, respiratory diseases, endocrine diseases, digestive system diseases, cardiovascular diseases, kidney diseases, nervous system diseases, immune diseases, tumors and the like.
Vitamin A is also called as retinol, which is mainly derived from animal liver in nature, and beta-carotene in plants can be converted into vitamin A in human body. Vitamin A is an essential substance for maintaining the normal functions of osteoblasts and osteoclasts and ensuring the normal metabolism of the osteoblasts. When the vitamin A of a human body is deficient, the change of bone deformation, abnormal cranial bone formation, low cure rate of bone injury, growth and development retardation and the like can be caused. The vitamin A deficiency and iron deficiency anemia in children are two diseases of nutrition deficiency in developing countries, and in China, anemia is one of four diseases of children.
DHA is most abundant in the brain, sperm, optic nerve and retina, but has limited capacity to synthesize DHA (less than 1% to 5%), particularly in fetuses, infants and children. Therefore, the body still needs to obtain DHA exogenously and directly to meet the needs of brain development and other life activities.
Folic acid is not synthesized in the body and must be supplied by food, especially green vegetables. Folic acid plays an important role in the synthesis of protein and nucleic acid and the metabolism of various amino acids, and is an essential nutrient for the healthy growth and development of fetuses, newborns and children. Folic acid has the function of promoting the maturation of immature cells in bone marrow, and a series of clinical manifestations such as sallow complexion, thin hair, puffiness, pale mucous membrane, diarrhea, anorexia and the like can be caused if the deficiency occurs.
Probiotics are viable microorganisms with a certain number that are beneficial to the health of the host. Various foods containing probiotics, such as yogurt, sauerkraut, cheese, etc., are common in life. The probiotics are beneficial bacteria which are symbiotic with human beings, can regulate intestinal flora, consolidate the barrier function of intestinal mucosa and stimulate the immune response of organisms. Such as lactic acid produced by fermentation of lactic acid bacteria, can improve the predigestion of food in stomach, improve the utilization rate of calcium, phosphorus and iron, and improve the absorption of vitamin D.
According to a second aspect of the present application, there is provided a process for the preparation of the above composition, the process comprising:
mixing mixture containing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid and retinol acetate, and stirring to obtain the composition;
the medium chain triglyceride, the milk mineral salt, the DHA powder, the cholecalciferol, the probiotic powder, the folic acid and the retinol acetate are added according to the mass ratio.
Optionally, the mixture further comprises auxiliary materials; the mass ratio of the auxiliary material to the medium-chain triglyceride is 525-635: 50-65.
According to a final aspect of the application, there is provided a use of at least one of the above composition and the composition prepared according to the above method in the preparation of a health food for promoting growth and development of children.
Interpretation of terms: g/kg · bw: dosage unit, g/kg body weight.
Daily usage amount: 10 g/day.
The beneficial effects that this application can produce include:
at present, the commonly used methods for promoting the growth and development of children include a food supplement method, a nutrient supplement mixed food method and the like. But the food nourishing method has little effect and has higher requirements on the nutrition knowledge storage of parents, the diet concept and the matching degree of children; improper diet of traditional Chinese medicines may cause potential safety hazards to the health of children; aiming at the problems that the nutrient supplements for children are various in types, the combined effect is not clear, and the nutrient proportion imbalance is difficult to guarantee for the healthy growth of the children. The market is lack of nutritional food which has good safety, exact effect and convenient taking and can promote growth and development.
Detailed Description
The present application will be described in detail with reference to examples, but the present application is not limited to these examples.
The raw materials in the examples of the present application were all purchased commercially, unless otherwise specified.
In the embodiment of the application, the probiotic powder is prepared from galactooligosaccharide, stachyose and bifidobacterium animalis Bb-12 according to the mass ratio of 15:10: 1.
The adjuvants in the examples of the present application are all malto-oligosaccharide powders: white granulated sugar powder: maltodextrin, 2: the ascorbic acid is prepared by uniformly mixing the ascorbic acid with the mass ratio of 20:10:30: 1.
The DHA powder used in the embodiment is Jiabiyou, the DHA content is more than or equal to 10 wt%, and the DHA powder is purchased.
Example 1:
formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
Example 2:
formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
Example 3:
formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
Example 4:
formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
Example 5:
formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
Example 6:
formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
Example 7:
formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
COMPARATIVE EXAMPLE 1 (COMPARATIVE FORMATION)
Formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
COMPARATIVE EXAMPLE 2 (formulation COMPARATIVE)
Formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
COMPARATIVE EXAMPLE 3 (COMPARATIVE FORMULATION)
Formulation 1000g (10 g/100 parts)
The process comprises the following steps:
1) mixing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid, retinol compound and adjuvants.
2) Subpackaging with 10g per bag.
Test example 1
The powders obtained in examples 1 to 7 were examined for organoleptic, moisture and nutrient contents at 0, 3 and 6 months.
Detecting the contents of water, calcium, phosphorus, vitamin A, D, folic acid and DHA and animal bifidobacteria according to GB/T5009.3, GB/T5009.92, GB/T5009.87, GB/T5009.82, GB/T5009.211, GB/T5009.168 and GB/T4789.34 respectively, and comparing the changes of sense and nutrient contents in 0-6 months. The results are shown in Table 1.
TABLE 1 evaluation results of the powders obtained in examples 1 to 7 and sensory and moisture nutrient contents in 0, 3 and 6 months
The analysis of the data in the table above shows that the moisture content of the powder prepared in examples 1-7 in 0, 3 and 6 months is below 7.0% required by GB/T29602, the calcium-phosphorus ratio is stable, the nutrient stability is good, the active probiotics exceeds 20 hundred million CFU/part, and the powder and the dissolved powder have no abnormal color, fragrance and taste and no bad smell. The specific proper proportion of the formula of the invention has good result under the condition of stability, and the obtained product has satisfactory effect.
Visual testing example 2
In order to compare the effects of improving growth and development of the present invention in examples 1, 2 and 7 and comparative examples 2 and 3, male weaning mice 60 were selected to be divided into six groups and administered with the samples of examples 1, 2 and 7 and the samples of comparative examples 2 and 3 and a control group (the control group is not administered with any sample).
TABLE 2 comparison of the growth-promoting effects of the animal experiments of examples 1, 2 and 7 and comparative examples 2 and 3
As can be seen from the above test results, examples 1, 2 and 7 have the effect of promoting growth and development, and examples 1, 2 and 7 have a significant difference in length and weight higher than comparative examples 2, 3 and control group after the samples of examples 1, 2 and 7 are taken for 14, 28 and 42 days compared with comparative examples 2, 3 and control group.
Test example 3
In order to compare the effects of promoting the growth and development of children and the adverse reactions of the examples 1, 4 and 6 of the present invention with those of the comparative example 1, 150 children of the subject were selected as five groups and the samples of the examples 1, 4 and 6 and the sample of the comparative example 1 were administered respectively. Subject inclusion criteria: organophilic diseases, height or weight below 6-10 years of age within 1 standard deviation of the mean level of the same age group; the observation indexes of efficacy are as follows: the height, weight, chest circumference and upper arm circumference were measured after 3 months and 6 months. Control group (control group did not take any sample, did not change the original eating habits), results are shown in table 3:
TABLE 3 comparison of growth and development promoting effects and adverse reactions of examples 1, 4, 6 and comparative example 1
As can be seen from the above test results, examples 1, 4 and 6 have the effect of promoting growth and development, and examples 1, 4 and 6 have a higher height, weight, chest circumference and upper arm circumference than comparative example 1 and the control group after the samples of examples 1, 4 and 6 are taken for 3 months and 6 months, compared with comparative example 1 and the control group, and have significant difference. And the embodiment has good safety and no adverse reaction.
Test example 4
To confirm the safety of the present invention, acute radial toxicity tests were performed using Kunming female and male mice. The result shows that the maximum tolerance dose of the invention to female and male Kunming mice is more than 20 g/kg-bw, and the invention belongs to non-toxic grade. And (3) genetic toxicity test: the Ames test, mouse marrow pleochromocyte nucleus test and mouse sperm malformation test result are all negative. The experimental results show that the invention has good safety.
Although the present application has been described with reference to a few embodiments, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the application as defined by the appended claims.
Claims (9)
1. A composition, comprising the following components:
50-65 parts by weight of medium chain triglyceride;
80-120 parts of milk mineral salt;
80-120 parts of DHA powder;
0.0006 to 0.001 weight part of cholecalciferol;
150 portions of probiotic powder and 180 portions of probiotic powder;
0.018-0.03 weight portion of folic acid;
0.015-0.025 parts by weight of retinol acetate;
the DHA powder contains DHA with the mass content of more than or equal to 10%.
2. The composition of claim 1, wherein the probiotic powder comprises bifidobacterium animalis Bb-12 and prebiotics.
3. The composition according to claim 2, wherein the mass ratio of the prebiotics to the bifidobacterium animalis Bb-12 is 20-25: 1.
4. The composition of claim 1, further comprising an adjuvant; the adjuvant is at least one selected from oligomeric maltose powder, white granulated sugar powder, maltodextrin, and ascorbic acid.
5. The composition as claimed in claim 4, wherein the mass ratio of the adjuvant to the medium chain triglyceride in the composition is 525-635: 50-65.
6. The composition according to claim 4, characterized in that it consists of:
50-65 parts by weight of medium chain triglyceride;
80-120 parts of milk mineral salt;
80-120 parts of DHA powder;
0.0006 to 0.001 weight part of cholecalciferol;
150 portions of probiotic powder and 180 portions of probiotic powder;
0.018-0.03 weight portion of folic acid;
0.015-0.025 parts by weight of retinol acetate;
the auxiliary material 525 and 635;
preferably, the composition is a powder.
7. A process for the preparation of a composition according to any one of claims 1 to 6, characterized in that it comprises:
mixing mixture containing medium chain triglyceride, milk mineral salt, DHA powder, cholecalciferol, probiotic powder, folic acid and retinol acetate, and stirring to obtain the composition;
the medium chain triglyceride, the milk mineral salt, the DHA powder, the cholecalciferol, the probiotic powder, the folic acid and the retinol acetate are added according to the mass ratio of the claim 1.
8. The method of claim 7, wherein the mixture further comprises an adjuvant; the mass ratio of the auxiliary material to the medium-chain triglyceride is 525-635: 50-65.
9. Use of at least one of the composition according to any one of claims 1 to 6, the composition prepared by the method according to claim 7 or 8, in the preparation of a health food for promoting growth and development of children.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110892765.0A CN113729211A (en) | 2021-08-04 | 2021-08-04 | Composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110892765.0A CN113729211A (en) | 2021-08-04 | 2021-08-04 | Composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113729211A true CN113729211A (en) | 2021-12-03 |
Family
ID=78730064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110892765.0A Pending CN113729211A (en) | 2021-08-04 | 2021-08-04 | Composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113729211A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115462526A (en) * | 2022-09-24 | 2022-12-13 | 陕西佰诺兮生物科技有限公司 | Weight management composition containing plant exosomes |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108477622A (en) * | 2018-04-16 | 2018-09-04 | 赵成群 | A kind of infant's global function alimentation composition |
| CN110074397A (en) * | 2019-04-03 | 2019-08-02 | 上海奥医生物医药科技有限公司 | A kind of upgrowth and development of children tailored version clinical nutrition formula and preparation method thereof |
| US20190335796A1 (en) * | 2014-09-01 | 2019-11-07 | Jolly Mathew Vadakkemuri | Optimized nutrient food |
| CN110754530A (en) * | 2019-11-04 | 2020-02-07 | 李钟� | Formula milk powder capable of effectively promoting height development of children and production method thereof |
| CN111264632A (en) * | 2020-02-27 | 2020-06-12 | 青岛索康食品有限公司 | Children formula milk powder for promoting calcium growth and preparation method thereof |
| CN112167348A (en) * | 2020-10-22 | 2021-01-05 | 成都诺臻生物科技有限公司 | Formula milk powder for promoting growth and development of children and preparation method thereof |
| CN112535283A (en) * | 2020-12-01 | 2021-03-23 | 北京华氏开元医药科技有限公司 | Total nutrient formula powder |
-
2021
- 2021-08-04 CN CN202110892765.0A patent/CN113729211A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190335796A1 (en) * | 2014-09-01 | 2019-11-07 | Jolly Mathew Vadakkemuri | Optimized nutrient food |
| CN108477622A (en) * | 2018-04-16 | 2018-09-04 | 赵成群 | A kind of infant's global function alimentation composition |
| CN110074397A (en) * | 2019-04-03 | 2019-08-02 | 上海奥医生物医药科技有限公司 | A kind of upgrowth and development of children tailored version clinical nutrition formula and preparation method thereof |
| CN110754530A (en) * | 2019-11-04 | 2020-02-07 | 李钟� | Formula milk powder capable of effectively promoting height development of children and production method thereof |
| CN111264632A (en) * | 2020-02-27 | 2020-06-12 | 青岛索康食品有限公司 | Children formula milk powder for promoting calcium growth and preparation method thereof |
| CN112167348A (en) * | 2020-10-22 | 2021-01-05 | 成都诺臻生物科技有限公司 | Formula milk powder for promoting growth and development of children and preparation method thereof |
| CN112535283A (en) * | 2020-12-01 | 2021-03-23 | 北京华氏开元医药科技有限公司 | Total nutrient formula powder |
Non-Patent Citations (2)
| Title |
|---|
| （英）菲尔•多布森（PHIL DOBSON）: "《脑力赋能》", vol. 1, 30 November 2019, 科学技术文献出版社, pages: 190 - 192 * |
| 黄德骧等: "《临床静脉营养》", vol. 1, 31 January 1994, 上海医科大学出版社, pages: 121 - 131 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115462526A (en) * | 2022-09-24 | 2022-12-13 | 陕西佰诺兮生物科技有限公司 | Weight management composition containing plant exosomes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112535283A (en) | Total nutrient formula powder | |
| CN108244252A (en) | Probiotics multielement protein powder and preparation method thereof | |
| CN108077911A (en) | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof | |
| CN102740865A (en) | Mitochondrial function improver | |
| CN110074397A (en) | A kind of upgrowth and development of children tailored version clinical nutrition formula and preparation method thereof | |
| CN103844249A (en) | Nutritional food, and preparation method thereof | |
| CN112998080A (en) | Infant formula milk powder added with yolk phospholipid, soybean phospholipid and milk phospholipid | |
| CN102753183A (en) | Agent for improving motility function | |
| CN103271166A (en) | Soybean whey composite powder and preparation method thereof | |
| CN105432792A (en) | Basic nutrition milk powder for preschool children, nutrition milk powder suit and preparation methods | |
| EA011075B1 (en) | Dry powdered milk formula | |
| CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
| CN109965271A (en) | A kind of children's brain growth tailored version clinical nutrition formula and preparation method thereof | |
| CN109156530A (en) | A kind of diatery supplement nutrition packet and its production technology | |
| CN110214942A (en) | A kind of hyperthyroidism tailored version Nutrition formula and preparation method thereof | |
| CN113729211A (en) | Composition and preparation method and application thereof | |
| KR20190091768A (en) | Health assistance food for promoting growth | |
| CN114190441A (en) | Formula milk powder for promoting growth and development of children and preparation method thereof | |
| CN109452369A (en) | It is a kind of to receive cream and its preparation method and application containing milk powder | |
| US20210037854A1 (en) | Eggs rich in nutrients of alpha-linolenic acid and dha, breeding method of laying hens, and feed additive | |
| CN110623073A (en) | Formula milk powder beneficial to body height and preparation method thereof | |
| Novhorodska | Sour milk drink with prebiotic properties | |
| CN105192698B (en) | A kind of health food containing leaf of Moringa powder and preparation method thereof | |
| CN109845826A (en) | A kind of infant milk powder for simulating breast milk fatty acids structure and composition | |
| Nadimin et al. | ‘Nutritional intervention based on moringa leaf flour to prevent stunting in first 1000 days of life (1000 HPK): Review articles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |